Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG), commonly referred to as the "dual trigger" in assisted reproductive technology. The GnRH agonist stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), mimicking the natural mid-cycle LH surge required for final oocyte maturation. hCG is administered alongside to further support oocyte maturation and luteal phase function. This combination aims to optimize oocyte maturation, improve pregnancy outcomes, and reduce the risk of ovarian hyperstimulation syndrome compared with hCG alone or GnRH agonist alone[6]. The dual trigger approach is primarily used in controlled ovarian stimulation cycles for in vitro fertilization–intracytoplasmic sperm injection (IVF–ICSI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gonadotropin-releasing hormone agonist + human chorionic gonadotropin.